CHELSEA REESE: Open Payments
NPI 1831680933 · BEAUMONT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$586 in 30 payments from 12 companies in 2025. Trend: 2023 $722 · 2024 $1,612 · 2025 $586
Food & beverage: $586
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 5 | $135 |
| ABBVIE INC. | 5 | $99 |
| Arcutis Biotherapeutics, Inc. | 3 | $56 |
| Galderma Laboratories, L.P. | 3 | $51 |
| MAYNE PHARMA COMMERCIAL LLC | 4 | $49 |
| GENZYME CORPORATION | 1 | $48 |
| Organon LLC | 3 | $38 |
| UCB, Inc. | 2 | $33 |
| Paratek Pharmaceuticals, Inc. | 1 | $27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
Products named: DUPIXENT, SKYRIZI, Zoryve, NEMLUVIO, RINVOQ, Bimzelx, LIBTAYO, NUZYRA.
Industry payments across TX — which companies pay providers there.
